G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Ammonia: a diffusible factor released by proliferating cells that induces autophagy.
Guillermo Mariño,Guido Kroemer +1 more
TL;DR: Intriguingly, cancer cells increase the rate glutaminolysis and the interstitial fluid of cancers contains higher-than-normal physiological concentrations of ammonia, suggesting a previously unknown pathway through which tumor cells can condition their microenvironment.
Journal ArticleDOI
Trial Watch: Radioimmunotherapy for oncological indications
Norma Bloy,Gwenola Manic,Ilio Vitale,Alexander M.M. Eggermont,Jérôme Galon,Eric Tartour,Laurence Zitvogel,Guido Kroemer,Lorenzo Galluzzi +8 more
TL;DR: Recent advances in the use of ionizing rays as a means to induce or potentiate therapeutically relevant anticancer immune responses are summarized and clinical trials initiated during the past 12 months are presented.
Journal ArticleDOI
The mitochondrial permeability transition pore complex as a pharmacological target. An introduction.
Book ChapterDOI
Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models.
TL;DR: This chapter will introduce the "gold standard" protocol for the in vivo assessment of ICD in mice, which relies on vaccination with treated cancer cells, followed by rechallenge with living entities of the same type, in syngeneic immunocompetent animals.
Journal ArticleDOI
eIF2α phosphorylation: A hallmark of immunogenic cell death
TL;DR: It is shown that eIF2α phosphorylation is a quintessential hallmark of ICD that can be detected by immunohistochemistry in tumor samples and hence is a classic hallmark of anticancer chemotherapeutics.